Literature DB >> 24117419

Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives.

Joseph V Pergolizzi1, Robert Taylor, Srinivas Nalamachu, Robert B Raffa, Douglas R Carlson, Ravi K Varanasi, Ernest A Kopecky.   

Abstract

OBJECTIVE: Dysphagia--difficulty eating and swallowing--can significantly impair a patient's ability to maintain adequate nutritional and medication intake. There are a large number of patients with chronic pain, including pediatric, geriatric, and palliative care patients, who suffer from dysphagia and, therefore, have difficulty achieving optimal pain management with solid, oral formulations. The objective of this study was to survey physicians and patients in the US to understand their knowledge, attitudes, and clinical management/analgesic usage patterns in the treatment of patients with chronic pain with dysphagia (CPD). RESEARCH DESIGN AND METHODS: Two separate surveys were administered to physicians and patients. The physician survey design was qualitative; physicians participated in a semi-structured phone interview. The patient survey design was quantitative; patients participated in a structured online survey. Purposive sampling was used to recruit participants into both studies. Physician participants were identified based on their specialty, prescribing practices, and geographic location. Patient participants were recruited through a consumer panel of pre-identified individuals who, for 3 months or longer, had chronic pain and were taking opioids.
RESULTS: Thirty-four physicians and 1021 patients were surveyed. Physicians indicated that 5-20% of their patients had difficulty swallowing. Treatment for CPD consisted of the fentanyl patch, immediate-release opioids, methadone liquid, or extended-release morphine products. Physicians were not satisfied with currently available treatment options. Twenty-nine per cent of patients surveyed had trouble swallowing or disliked swallowing pills. Eighty per cent of patients were not asked about their ability to swallow solid, oral dosage forms by their physician. To circumvent swallowing difficulties, some patients (16%) cut/crush/grind their medication to facilitate swallowing. Most of these patients (65%) did not know that altering tablets could potentially change the drug release (pharmacokinetic) characteristics of the tablet and lead to serious adverse events. LIMITATIONS: Qualitative survey research can be influenced by responder bias as well as selection bias. The number of survey participants for both the physician and patient surveys was small, thus responses may not reflect those in the general population.
CONCLUSION: A proportion of patients with chronic pain have dysphagia and cannot swallow solid, oral dosage forms, which creates a serious treatment challenge for pain specialists and other healthcare providers. Currently available treatment options have limitations; new treatment options would be welcomed by both physicians and patients. Physician and patient education should be enhanced in order to promote awareness of the deleterious consequences associated with altering currently available analgesic formulations. Facilitating patient-physician communication on this topic may help to improve treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24117419     DOI: 10.1185/03007995.2013.854197

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  9 in total

Review 1.  The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.

Authors:  Nalini Vadivelu; Erika Schermer; Gopal Kodumudi; Jack M Berger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 2.  Options for Treating Pain in Cancer Patients with Dysphagia.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 4.  Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain.

Authors:  Jeff Gudin
Journal:  Pain Ther       Date:  2016-11-21

5.  Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.

Authors:  Ernest A Kopecky; Ben Vaughn; Scott Lagasse; Melinda O'Connor
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 3.923

6.  Response to Crudele et al. Commentary on Gudin et al. "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties".

Authors:  Jeff Gudin; Ernest A Kopecky; Alison B Fleming
Journal:  Pain Med       Date:  2017-05-01       Impact factor: 3.750

7.  Use of a Long-Acting Opioid Microsphere Formulation to Overcome Difficulties in Swallowing Pain Medication.

Authors:  Nathan Anderson; Andrea G Gillman; Ajay D Wasan
Journal:  J Pain Res       Date:  2020-05-06       Impact factor: 3.133

8.  Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).

Authors:  Ernest A Kopecky; Alison B Fleming; Naama Levy-Cooperman; Melinda O'Connor; Edward M Sellers
Journal:  J Clin Pharmacol       Date:  2016-11-01       Impact factor: 3.126

9.  In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations.

Authors:  Stephen P Mayock; Said Saim; Alison B Fleming
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 3.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.